{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:34:01Z","timestamp":1794317641127,"version":"4.9.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ad.2022.07.021","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T18:45:17Z","timestamp":1661625917000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Quality of Life and Body Region Affected by Psoriasis: A Systematic Review"],"prefix":"10.1016","volume":"114","author":[{"given":"K.","family":"Nabieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2022.07.021_bib0290","first-page":"78","article-title":"Differences between psoriasis patients and skin-healthy controls concerning appraisal of touching, shame and disgust","volume":"96","author":"Lahousen","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0295","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ad.2022.07.021_bib0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ad.2022.07.021_bib0305","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0310","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2230.1987.tb01844.x","article-title":"Psoriasis\u2014an index of disability","volume":"12","author":"Finlay","year":"1987","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0315","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ad.2022.07.021_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/2046-4053-3-54","article-title":"Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram","volume":"3","author":"Stovold","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.ad.2022.07.021_bib0325","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2133.2003.04950.x","article-title":"Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients","volume":"148","author":"Andreassi","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0330","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjd.17403","article-title":"Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients","volume":"181","author":"Augustin","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0335","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/jocd.12513","article-title":"Turmeric tonic as a treatment in scalp psoriasis: a randomized placebo-control clinical trial","volume":"17","author":"Bahraini","year":"2018","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0340","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jdv.14647","article-title":"Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0345","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000504841","article-title":"Characterization of patients with psoriasis in challenging-to-treat body areas in the corrona psoriasis registry","volume":"237","author":"Duffin","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2022.07.021_bib0350","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2014.04.063","article-title":"Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis","volume":"71","author":"Chung","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0355","first-page":"1011","article-title":"Shedding light on the \u201chidden psoriasis\u201d: a pilot study of the inverse psoriasis burden of disease (IPBOD) questionnaire","volume":"15","author":"Cohen","year":"2016","journal-title":"JDD"},{"key":"10.1016\/j.ad.2022.07.021_bib0360","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jdv.16076","article-title":"Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for person-centred healthcare of emerging adults and adults","volume":"34","author":"Da Silva","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0365","first-page":"1","article-title":"Sex-related impairment and patient needs\/benefits in anogenital psoriasis: difficult-to-communicate topics and their impact on patient-centred care","volume":"15","author":"Silva","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2022.07.021_bib0370","doi-asserted-by":"crossref","first-page":"1795964","DOI":"10.1080\/2331205X.2020.1795964","article-title":"Effects of a topical ointment on responses to treatments used for common genital diseases and on quality of life","volume":"7","author":"de Belilovsky","year":"2020","journal-title":"Cogent Med"},{"key":"10.1016\/j.ad.2022.07.021_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12895-020-00099-7","article-title":"Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort","volume":"20","author":"Egeberg","year":"2020","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0380","first-page":"123","article-title":"Depression and quality of life in psoriasis and psoriatic arthritis patients","volume":"14","author":"Ghajarzadeh","year":"2011","journal-title":"Iran J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0385","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0390","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/09546634.2015.1093590","article-title":"Topical treatment for scalp psoriasis: comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol\/betamethasone gel in daily clinical practice","volume":"27","author":"Gual","year":"2016","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2022.07.021_bib0395","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10198-014-0600-x","article-title":"Exploring the relationship between EQ-5D DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary","volume":"15","author":"Her\u00e9di","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.ad.2022.07.021_bib0400","unstructured":"Imafuku S, Kanai Y, Murotani K, Nomura T, Ito K, Ohata C, et al. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: results from the ProLOGUE study. J Dermatol Sci."},{"key":"10.1016\/j.ad.2022.07.021_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-018-1007-7","article-title":"The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study","volume":"16","author":"Jung","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ad.2022.07.021_bib0410","first-page":"11","article-title":"Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice","volume":"26","author":"Khobzey","year":"2017","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.ad.2022.07.021_bib0415","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jdv.12368","article-title":"Nail psoriasis, the unknown burden of disease","volume":"28","author":"Klaassen","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0420","unstructured":"Kokolakis G, Bachmann F, Wolk K, Sabat R, Philipp S. Efficacy of adalimumab for nail psoriasis during 24 months of continuous therapy. Acta Dermato-venereol."},{"key":"10.1016\/j.ad.2022.07.021_bib0425","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1684\/ejd.2014.2399","article-title":"Quality of life and severity of skin and nail involvement in patients with plaque psoriasis","volume":"24","author":"Kyriakou","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0430","first-page":"1","article-title":"Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit","volume":"31","author":"Lanna","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2022.07.021_bib0435","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bjd.17147","article-title":"GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis","volume":"180","author":"Larsabal","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0440","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2009.03211.x","article-title":"Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis","volume":"23","author":"Luger","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0445","doi-asserted-by":"crossref","first-page":"109780","DOI":"10.1016\/j.jpsychores.2019.109780","article-title":"Quality of life, anxiety and depressive symptoms in patients with psoriasis: a case\u2013control study","volume":"124","author":"Mart\u00ednez-Ortega","year":"2019","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.ad.2022.07.021_bib0450","first-page":"916","article-title":"Improvement of quality of life and clinical usefulness of cyclosporin administration in patients with nail psoriasis","volume":"38","author":"Abe","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0455","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1365-2133.2011.10249.x","article-title":"Quality of life and sexual health in patients with genital psoriasis","volume":"164","author":"Meeuwis","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0460","doi-asserted-by":"crossref","first-page":"A612","DOI":"10.1016\/j.jval.2014.08.2147","article-title":"A comparative cross-sectional study on health-related quality of life in psoriasis from Hungary and Iran","volume":"17","author":"Moradi","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.ad.2022.07.021_bib0465","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/2475530318806256","article-title":"Fingernail involvement is a bigger burden than face and scalp involvement in patients with psoriasis","volume":"4","author":"Ohata","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.ad.2022.07.021_bib0470","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2009.03344.x","article-title":"Development and validation of nail psoriasis quality of life scale (NPQ10)","volume":"24","author":"Ortonne","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0475","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/ijd.14492","article-title":"Facial involvement and the severity of psoriasis","volume":"58","author":"Passos","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0480","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jdv.14581","article-title":"Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials","volume":"32","author":"Paul","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0485","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1590\/abd1806-4841.20175918","article-title":"Nail psoriasis treated with pulsed dye laser","volume":"92","author":"Peruzzo","year":"2017","journal-title":"Anais brasileiros de dermatologia"},{"key":"10.1016\/j.ad.2022.07.021_bib0490","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1067\/S0190-9622(03)01479-8","article-title":"Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice","volume":"49","author":"Pettey","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0495","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jdv.12198","article-title":"Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and\/or feet: post hoc analysis of REACH","volume":"28","author":"Poulin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0500","first-page":"1","article-title":"Real-world experience with apremilast: analysis of 250 patients from the APPRECIATE study with psoriasis in difficult-to-treat areas","author":"Augustin","year":"2019","journal-title":"AAD Annual Meeting"},{"key":"10.1016\/j.ad.2022.07.021_bib0505","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"18","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0510","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000317775","article-title":"Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial","volume":"221","author":"Reich","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2022.07.021_bib0515","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/jdv.12884","article-title":"Moderate to severe psoriasis patients\u2019 subjective future expectations regarding health-related quality of life and longevity","volume":"29","author":"Rencz","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0520","first-page":"e61","article-title":"Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study","volume":"163","author":"Richetta","year":"2012","journal-title":"Clin Ter"},{"key":"10.1016\/j.ad.2022.07.021_bib0525","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning","volume":"72","author":"Ryan","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0530","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/ijd.13307","article-title":"Clinical characteristics of patients with facial psoriasis in Malaysia","volume":"55","author":"Syed Nong Chek","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0535","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s11136-015-1224-z","article-title":"Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice","volume":"25","author":"Shear","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ad.2022.07.021_bib0540","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/1346-8138.12201","article-title":"Identification of psoriatic patients at risk of high quality of life impairment","volume":"40","author":"Sojevi\u0107 Timotijevi\u0107","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0545","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jdv.12553","article-title":"Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study","volume":"29","author":"Thaci","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.07.021_bib0550","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/myc.12681","article-title":"Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: results of a pilot study","volume":"60","author":"Tsentemeidou","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.ad.2022.07.021_bib0555","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0560","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/archderm.140.4.408","article-title":"Objective assessment of compliance with psoriasis treatment","volume":"140","author":"Zaghloul","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2022.07.021_bib0565","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s10103-018-2564-z","article-title":"Efficacy assessment of UVA1 and narrowband UVB for treatment of scalp psoriasis","volume":"33","author":"Zhou","year":"2018","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.ad.2022.07.021_bib0570","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jid.2019.03.668","article-title":"592 impact of scalp psoriasis on quality of life measurements at baseline and following treatment with ixekizumab","volume":"139","author":"Vaughn","year":"2019","journal-title":"J Investig Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731022007608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731022007608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:15:44Z","timestamp":1757553344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731022007608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0001731022007608"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2022.07.021","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life and Body Region Affected by Psoriasis: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2022.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}